Express News | CareDx Inc : Stephens Raises Target Price to $22 From $18
Where CareDx Stands With Analysts
Express News | Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $16
CareDx, Inc (NASDAQ:CDNA) Held Back By Insufficient Growth Even After Shares Climb 31%
CareDx to Report Second Quarter 2024 Financial Results
Nephron Initiates CareDx at Hold Rating With $15 Price Target
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
Express News | CareDx Inc : Jefferies Assumes Coverage With Buy Rating; Price Target $17 Vs $12
Decoding 6 Analyst Evaluations For CareDx
CareDx (CDNA) Gets a Hold From H.C. Wainwright
Express News | CareDx To Present New Data At The 2024 American Transplant Congress Being Held June 1-5 In Philadelphia
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
Express News | CareDx Shares Are Trading Lower. The Company Announced That It Responded to Natera's Filing of a Motion for an Injunction Related to Patent 11,111,544
CareDx Responds To Natera's Filing Of A Motion For An Injunction Related To Patent 11,111,544; CareDx Informed Natera And The Court, Since August 2023, CareDx Has Utilized A New Allosure Process That It Believes Does Not Infringe On The '544 Patent.
Express News | CareDx Inc - Underlying Validity of '544 Patent Also Remains Subject to Judicial Review.
Express News | CareDx Inc - Injunction Motion Has No Impact on Caredx's Business or Patient and Clinician Access to Allosure or Allomap
Express News | CareDx Reiterates Position That It Does Not Infringe the ‘544 Patent, Injunction Motion Is Irrelevant
CareDx to Participate in Upcoming Investor Conferences
Top 3 Health Care Stocks That May Crash In May